SOX10 Antibodies

Structure of SOX10

SOX10 is a transcription factor protein with a molecular weight of approximately 50-55 kDa. Its precise molecular weight may vary slightly depending on the species and transcript isomers. This protein belongs to the SOX (SPI-related HMG cassette) protein family, and its core structure is a highly conserved HMG domain (approximately 79 amino acids), mediating specific binding to DNA.

The SOX10 protein binds to the promoter or enhancer regions of target genes in a sequence-specific manner through its HMG domain, thereby regulating key processes such as neural crest development, myelin formation, and melanocyte differentiation. The N-terminal and C-terminal transcriptional activation domains of its protein are responsible for recruiting other co-activators and chromatin modification complexes to initiate gene expression.

Fig. 1 Schematic diagram of sgRNAs targeting at exons 1 and 2 of the human SOX10 locus.¹

Key structural properties of SOX10:

• Contains highly conserved HMG box (High Mobility Group box) DNA-binding domains
• With the c-terminal domain transcription activation structure
• Function through dimerization and interaction with other transcription factors such as PAX3

Functions of SOX10

The main function of the SOX10 gene is to act as a transcription factor to regulate the development and differentiation of neural crest cells. In addition, it is widely involved in a variety of key physiological processes such as the formation of the peripheral nervous system, melanocyte generation, and the development of the auditory system.

SOX10 exerts its function in monomer or dimer form by binding to a specific sequence (5'-AACAAT-3') in the promoter region of the target gene with high affinity through its HMG domain. Its regulation is highly synergistic and can activate downstream developmental pathways in various cellular environments.

Applications of SOX10 and SOX10 Antibody in Literature

1. Man, Ka-Hou, et al. "SOX10 mediates glioblastoma cell-state plasticity." EMBO reports 25.11 (2024): 5113-5140. https://doi.org/10.1038/s44319-024-00258-8

The article indicates that the low expression of SOX10 promotes the transformation of glioblastoma into a neural stem cell-like state, leading to treatment resistance. Inhibiting the Notch pathway can reduce this resting-state cell, and combining it with HDAC/PI3K inhibitors can prolong the survival of mice. This study provides a new strategy for therapies targeting phenotypic plasticity.

2. Capparelli, Claudia, et al. "Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma." Nature communications 13.1 (2022): 1381. https://doi.org/10.1038/s41467-022-28801-y

The article indicates that SOX10 deficiency induces phenotypic transformation in melanoma cells, endowing them with invasiveness and tolerance to BRAF/MEK inhibitors. cIAP1/2 inhibitors can selectively eliminate SOX10-deficient cells. When used in combination with BRAF/MEK inhibitors, they can delay the occurrence of drug resistance, providing a new treatment strategy for this type of tumor.

3. Waddell, Aaron, et al. "p300 KAT regulates SOX10 stability and function in human melanoma." Cancer Research Communications 4.8 (2024): 1894-1907. https://doi.org/10.1158/2767-9764.CRC-24-0124

The article indicates that SOX10 is a key factor for melanoma growth, but its absence can induce invasive and drug-resistant phenotypes. Research has found that EP300 stabilizes SOX10 protein through KAT activity. Its inhibitor A-485 can degrade SOX10, effectively inhibiting the proliferation of SOX10+ tumors and reducing the invasiveness of AXL High /MITFlow cells, providing A new strategy for targeted therapy.

4. Fogarty, Elizabeth A., Jacob O. Kitzman, and Anthony Antonellis. "SOX10-regulated promoter use defines isoform-specific gene expression in Schwann cells." BMC genomics 21.1 (2020): 549. https://doi.org/10.1186/s12864-020-06963-7

The article indicates that SOX10 dominates the expression of myelin-forming related gene subtypes in the peripheral nervous system by regulating specific promoters and transcription start sites in Schwann cells. Combining whole-genome analysis and functional experiments, the research has newly discovered four SOX10 target genes, including ARPC1A, providing new insights into the mechanism of myelin formation.

5. Correa-Arzate, Lorena, et al. "LRP5, SLC6A3, and SOX10 expression in conventional ameloblastoma." Genes 14.8 (2023): 1524. https://doi.org/10.3390/genes14081524

The article indicates that SOX10, SLC6A3 and LRP5 jointly promote the proliferation and invasion of ameloblastoma, and high expression is associated with a poor prognosis. Research has found that parthenolide and vorinostat can inhibit these genes, providing a new direction for targeted therapy.

Creative Biolabs: SOX10 Antibodies for Research

Creative Biolabs specializes in the production of high-quality SOX10 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom SOX10 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our SOX10 antibodies, custom preparations, or technical support, contact us at email.